ARPA Bio
in tune with innovative solutions for early therapeutic intervention...
Analysis of CSF and blood based biomarkers using ARPA Bio's proprietary platform:
ARPA Bio's analytical platform enables the detection of low abundant CSF and plasma biomarkers at the femto to picogram / ml level. We apply our novel antibody tools in combination with the latest, state-of-the-art mass spectrometry technology, to monitor disease specific biomarkers in human biofluid. Our analytical approach allows absolute quantification of multiple disease associated targets of interest during a single analytical run. This in turn enables monitoring of early disease onset or progression, as well as a patient's response to a therapeutic treatment.
More specific information about our technology will be announced soon....
Novel approach in measuring longitudinal changes of specific biomarkers in one single analytical shot.
The proprietary ARPA-tag-code approach allows for multiplexing different samples, either from different individuals or for measuring changes in absolute values of specific biomarkers in a patient over different time points (days or months, below). The key advantage of using this analytical apprach is that the ARPA-tags were designed to have unique analytical properties in such as improved solubility and can be long-term stored or shipped to central labs for future analysis without any significant analytical bias (due to storage) in reference tag (biomarker) readout. ARPA uses a combination of proprietary antibodies against specific early biomarkers in urine, CSF or plasma (blood), together with an AI curated omics database to improve the diagnostic readout but, more importantly, to improve early diagnosys of different disease indications. This in turn will allow early therapeutic intervention and therefore slow disease progression prior to clincal manifestation of severe symptoms. Beside our strong focus on neurodegenerative diseases, ARPA aims to apply this diagnostic approach for different disease indications with a clear unmet medical need and that still lack early clincal biomarker profiles and where current clinical biomarker profiles typically show strong fluctuations as a result of the patient's life style or environmental changes.
